All Clarivate Analytics websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.

More information on our cookie policy.

BioWorld. Link to homepage.

/images/Cortellis_Flagship_Logo_TM_RGB_Color.png
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
  • Special reports
    • Artificial intelligence
    • Coronavirus
    • Diagnosing and tracking COVID-19
    • Drugs to Watch 2020
    • The next pandemic
    • Premium reports
      • BioWorld Financings Reports
      • Disease Forecast Reports

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Saturday, April 17, 2021
Home » Topics » Deals and M&A

Deals and M&A
%{topic} RSS Feed RSS

Evoq captures $240M autoimmune development deal with Amgen

Jan. 13, 2021
By Michael Fitzhugh
No Comments
Evoq Therapeutics LLC, a Michigan-based company developing a new technology for treating autoimmune disease, has signed a new license and collaboration agreement giving Amgen Inc. exclusive rights to selected programs in the area, undisclosed in number and indication. Valued at more than $240 million in up-front and milestone payments, the deal also includes potential royalties on sales of resulting therapies, Evoq said.
Read More
DNA on digital background

Screen savior? KSQ’s CRISPRomics bags major Takeda deal

Jan. 13, 2021
By Randy Osborne
No Comments
KSQ Therapeutics Inc.’s chief scientific officer, Frank Stegmeier, said that the CRISPRomics technology that drew Takeda Pharmaceutical Co. Ltd. to the table allows, “for the first time, genome-scale functional screening [in vivo as well as in vitro] across multiple disease settings. It really takes the guessing game out of your drug target selection.” Working with “an encyclopedia of gene function,” he said, KSQ aims to identify prospects that can have monotherapy activity in PD-1-refractory solid tumors.
Read More

Merck joins SHP2 players in expanded Astex-Taiho deal

Jan. 13, 2021
By Nuala Moran
No Comments
LONDON – Merck & Co. Inc. has become the latest pharma company to in-license a SHP2 small-molecule program, as the rush to find companion pieces for KRAS oncogene inhibitors heats up.
Read More
Deal handshake and arrows sketch on chalkboard

More than $1B in partnering deals keep last year’s momentum going

Jan. 12, 2021
By Lee Landenberger
No Comments
As a virtual 39th J.P. Morgan Annual Healthcare Conference begins, typically one of the biggest events of the year, biopharma dealmaking barreled ahead with five new deals Jan. 11 that could eventually hit $1.04 billion in total.
Read More
Handshake dollar sign

Steris to acquire Cantel Medical for $3.6B

Jan. 12, 2021
By Meg Bryant
No Comments
Steris plc has agreed to buy Cantel Medical Corp. for approximately $3.6 billion, in a cash and stock transaction that unites two key players in the infection prevention space. The combined company offers a number of synergies. Cantel’s medical portfolio is expected to bolster and expand Steris’ endoscopy offerings, with a full-suite of high-level disinfection consumables, capital equipment and services plus single-use accessories.
Read More
Handshake with cityscape and businesspeople

Robust deals hit $197B in 2020; M&As ready to rebound

Jan. 12, 2021
By Karen Carey
No Comments
With several deals and M&As falling within the highest values on record, 2020 turned out to be a solid year for the biopharma industry. Expectations are optimistic moving into 2021, when the U.S. will welcome a new president and its citizens should reach herd immunity from COVID-19.
Read More

Sanofi goes one step Biond checkpoint madness with $1B-plus cancer deal

Jan. 12, 2021
By Randy Osborne
No Comments
Biond Biologics Ltd. co-founder and CEO Tehila Ben-Moshe told BioWorld that “a relatively small group of scientists who are very motivated started with a very basic scientific idea, which we were able to take all the way into clinical trials in four years,” and draw the interest of Paris-based Sanofi SA in a checkpoint inhibitor with multi-cell effects. In its second major deal of the week, Sanofi is pledging $125 million up front and more than $1 billion more in potential development, regulatory and sales-related milestone payments to Biond, of Misgav, Israel.
Read More
Biotech deal illustration

Boehringer continues cancer investment in $1B deal with Enara

Jan. 12, 2021
By Lee Landenberger and Nuala Moran
No Comments
LONDON – Enara Bio Ltd. has landed the first major deal around its dark antigen technology platform, signing up Boehringer Ingelheim GmbH in an agreement worth a potential €876 million (US$1.06 billion). Reaching that figure would require a product to make it to market. More immediately, Enara is getting an up-front payment, research and preclinical milestones for each of up to three tumor types explored in the partnership.
Read More
Antibodies attacking cancer cell

Beigene inks $2.2B PD-1 deal with Novartis for cancer drug tislelizumab

Jan. 12, 2021
By Elise Mak
No Comments
BEIJING – Beigene Ltd. out-licensed its anti-PD-1 monoclonal antibody tislelizumab to Novartis AG in a deal worth up to $2.2 billion, including $650 million up front. Novartis gains rights to develop and commercialize tislelizumab in the U.S., Canada, Mexico, the EU, the U.K., Norway, Switzerland, Iceland, Liechtenstein, Russia and Japan.
Read More
Handshake with globe background and digital overlay

EY Report: Expect M&A to catch fire in 2021

Jan. 11, 2021
By Annette Boyle
No Comments
While the first quarter may be a little slow as the winter COVID-19 surge continues to disrupt business, expect high capital reserves in med tech and life sciences to make 2021 a year for brisk deal activity, according to the 2021 Ernst & Young (EY) M&A Firepower report. In 2020, industry M&A activity fell to the lowest levels since 2014, but the multinational audit and consulting firm found that the industry now has record levels of deal capacity that it is poised to use to accelerate growth coming out of the pandemic.
Read More
Previous 1 2 … 9 10 11 12 13 14 15 16 17 … 75 76 Next

Popular Stories

  • Free access to BioWorld coronavirus articles

    BioWorld

    The articles in this collection are from BioWorld’s ongoing coverage of the COVID-19 coronavirus outbreak. Note that we have added three critical tables which are...

  • Today's news in brief

    BioWorld
    BioWorld briefs for April 16.
  • IPO puzzle pieces

    Somalogic to merge with CM Life Sciences II SPAC, as trendy IPO path continues

    BioWorld MedTech
    Somalogic Inc. has agreed to go public via a merger with blank-check company CM Life Sciences II. Upon closing, CMLS II – a special purpose acquisition company...
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech's briefs for April 16.
  • Earth threatened by virus

    Global cases rise, but more weapons advance to combat COVID-19

    BioWorld
    As COVID-19 vaccinations continue to roll out, momentum builds with strong phase III data for what could become the fourth and fifth walls of defense in the U.S.
cortellis ad

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.

Subscribe
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • About
    • Archives
    • Today's news
    • Search BioWorld Science
  • More
    • About
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
A Clarivate Analytic solution. Link to Clarivate website.
Follow Us

Copyright ©2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing